BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $104.00 at Bank of America

BridgeBio Pharma (NASDAQ:BBIO) had its price objective lifted by stock analysts at Bank of America from $101.00 to $104.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 22.80% from the company’s current price.

BBIO has been the topic of several other research reports. Wells Fargo & Company upped their price target on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday. TD Cowen boosted their target price on BridgeBio Pharma from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday. Mizuho decreased their target price on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 16th. Raymond James Financial cut BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 26th. Finally, Truist Financial lifted their price target on BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.53.

BridgeBio Pharma Trading Up 0.0%

Shares of BBIO stock traded up $0.02 during trading hours on Tuesday, reaching $84.69. The stock had a trading volume of 1,245,358 shares, compared to its average volume of 2,992,219. The stock’s fifty day simple moving average is $76.07 and its 200 day simple moving average is $73.03. The firm has a market capitalization of $16.56 billion, a PE ratio of -22.66 and a beta of 0.96. BridgeBio Pharma has a 12 month low of $46.81 and a 12 month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million for the quarter, compared to analyst estimates of $220.91 million. During the same quarter in the previous year, the business earned ($0.95) earnings per share. The company’s revenue for the quarter was up 120.4% compared to the same quarter last year. As a group, equities research analysts anticipate that BridgeBio Pharma will post -2.31 EPS for the current fiscal year.

Insider Transactions at BridgeBio Pharma

In other news, Director Hannah Valantine sold 2,196 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total value of $150,579.72. Following the completion of the sale, the director owned 9,259 shares of the company’s stock, valued at approximately $634,889.63. This represents a 19.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer E. Cook sold 148,589 shares of BridgeBio Pharma stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the completion of the transaction, the director owned 8,383 shares in the company, valued at approximately $742,230.82. The trade was a 94.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 392,117 shares of company stock worth $29,934,700. Corporate insiders own 14.23% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC increased its position in shares of BridgeBio Pharma by 139.4% in the first quarter. Hsbc Holdings PLC now owns 32,708 shares of the company’s stock valued at $2,431,000 after acquiring an additional 19,043 shares during the period. Geode Capital Management LLC grew its stake in shares of BridgeBio Pharma by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 4,412,523 shares of the company’s stock worth $344,689,000 after purchasing an additional 502,582 shares during the last quarter. Nan Fung Trinity HK Ltd. purchased a new position in BridgeBio Pharma during the 4th quarter valued at about $8,422,000. Assetmark Inc. raised its position in BridgeBio Pharma by 423.7% during the 1st quarter. Assetmark Inc. now owns 20,790 shares of the company’s stock valued at $1,544,000 after purchasing an additional 16,820 shares during the last quarter. Finally, GW&K Investment Management LLC lifted its holdings in BridgeBio Pharma by 4.7% in the 4th quarter. GW&K Investment Management LLC now owns 626,122 shares of the company’s stock worth $47,892,000 after buying an additional 27,885 shares during the period. Institutional investors own 99.85% of the company’s stock.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Analysts raise targets: Piper Sandler increased its price target from $111 to $115 and maintained an “overweight” rating. Wells Fargo also raised its target, from $98 to $102, while keeping an “overweight” rating. The revisions imply substantial potential upside and reflect continued confidence in BridgeBio’s development pipeline. Benzinga analyst price-target updates
• Positive Sentiment: Pipeline catalysts could drive sentiment: BridgeBio is listed among biotech companies with major second-half 2026 catalysts, including potential regulatory decisions and late-stage clinical-trial readouts. Positive data or approvals could provide important valuation catalysts for BBIO. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Neutral Sentiment: Revenue growth was strong: Second-quarter revenue reached $243.7 million, beating the $220.9 million consensus estimate and increasing 120.4% from the prior year. The improvement suggests commercial and partnered-product activity is expanding, although investors remain focused on the company’s path toward profitability. BridgeBio Pharma Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Quarterly loss exceeded expectations: BridgeBio reported a second-quarter loss of $0.78 per share, wider than the $0.58 analyst consensus, despite improving from a $0.95 loss per share a year earlier. The earnings miss may limit the stock’s near-term upside and reinforce concerns about ongoing cash needs and operating costs. BridgeBio Pharma Q2 Earnings Results and Conference Call

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.